Circulogene is excited to announce the exclusive commercial launch of LungLifeAI, a breakthrough AI-driven blood-based test designed to improve clinical decision-making in patients with indeterminate pulmonary nodules detected through CT scans.
When a lung nodule is discovered on a CT scan, deciding whether to proceed with a biopsy—especially for nodules smaller than 2 cm—can be difficult. LungLifeAI helps close this gap by delivering high-performance molecular biomarker analysis to support informed biopsy decisions. Clinically validated, LungLifeAI offers an 80% Positive Predictive Value, 77% sensitivity, and 74% specificity, enabling earlier and more accurate malignancy assessment.
Health Technology Insights: ClinTrial Partners with Trially AI to Boost Enrollment
Circulogene Announces Exclusive Commercial Launch of LungLifeAI
Using a simple blood collection kit—with mobile phlebotomy options available—LungLifeAI streamlines the diagnostic process for patients and providers. The test uses advanced AI to analyze chromosomal signal patterns in thousands of cells, offering deep molecular insight into nodule behavior and risk.
Health Technology Insights: Pager Health and Protera Health Partner for Virtual MSK Care
“Our physicians need greater clarity when assessing patients with indeterminate pulmonary nodules,” said Mike Mullen, CEO of Circulogene. “LungLifeAI complements our OncoGenLDx tumor profiling test by providing actionable insight when CT imaging isn’t enough. With a simple blood draw, we help physicians determine which small nodules require biopsy for a timely treatment plan.”
Health Technology Insights: Castlight Health Expands Partnership with ArcBest for Primary Care
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
